secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001213900-25-075014
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports Q3 net loss $5.4M; LYMPHIR launch on track for Q4 2025
------------------------------------------------------------------------------

- Net loss of $5.4M ($0.08/share) for fiscal Q3 ended June 30, 2025, vs $4.8M ($0.07) a year ago.
- LYMPHIR commercial launch planned for Q4 2025; launch supplies and distribution agreements in place.
- Raised $12.5M gross from parent equity offerings in Q3; Citius Oncology raised additional $9M in July 2025.
- On July 17, 2025, closed public offering with net proceeds of approximately $7.4M.
- Cash and cash equivalents were $112 as of June 30, 2025, subsequently improved by July financings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/0001213900-25-075014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/ea0252884-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-075014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer